Feasibility of self-sampling and human papillomavirus testing for cervical cancer screening in First Nation women from Northwest Ontario, Canada: a pilot study

Ingeborg Zehbe, Helle Moeller, Alberto Severini, Bruce Weaver, Nicholas Escott, Crystal Bell, Sandra Crawford, Diane Bannon, Natalie Paavola, Ingeborg Zehbe, Helle Moeller, Alberto Severini, Bruce Weaver, Nicholas Escott, Crystal Bell, Sandra Crawford, Diane Bannon, Natalie Paavola

Abstract

Background The incidence of cervical cancer is up to sixfold higher among First Nation women in Canada than in the general population. This is probably due to lower participation rates in cervical cancer prevention programmes. Objective To raise screening participation in this underserved population by launching an alternative approach to (Pap)anicolaou testing in a clinic-namely, vaginal self-sampling followed by human papillomavirus (HPV) diagnostics. Methods Good relationships were established with a First Nation community of the Northern Superior region in Northwest Ontario, and then 49 community women, aged 25-59, were recruited, who provided a vaginal self-sample and answered a questionnaire. Frequency distributions and cross-tabulations were used to summarise the data. Associations between categorical variables were assessed using the χ(2) test of association, or the Goodman-Kruskal γ if both variables had ordered categories. Self-collected samples were tested for integrity and HPV using optimised molecular biological methods. Results The majority of participants (87.2%) were amenable to future HPV screening by self-sampling. This finding was independent of age, educational level and a previous history of abnormal Pap tests. Interestingly, the preferred way to learn about sexual health remained through interaction with healthcare professionals. As defined by the presence of a housekeeping gene, self-sample integrity was high (96%). Using polymerase chain reaction-based Luminex typing, the overall HPV positivity was 28.6% (ie, with either a low- or high-risk type) and 16.3% were infected with a high-risk type such as HPV16. Conclusion In this pilot study of First Nation women, self-sampling and HPV testing was well received and self-sample quality was excellent. A larger survey to be conducted in other Northern Superior communities in Northwest Ontario will determine whether this approach could become a viable screening strategy for First Nation women.

Conflict of interest statement

Competing interests: There are no industry relationship with the present study.

References

    1. Saslow D, Castle PE, Cox JT, et al. American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin 2000;57:7–28
    1. Health Canada. Cervical Cancer Screening in Canada: 1998 Surveillance Report. 2002.
    1. Corriveau A. Cancer incidence and mortality in the NWT 1991 to 1996. Epi-North 1997;9:5
    1. Young TK, Kliewer E, Blanchard J, et al. Monitoring disease burden and preventative behavior with data linkage: cervical cancer among aboriginal people in Manitoba, Canada. Am J Public Health 2000;90:1466–8
    1. Marrett LD, Chaudhry M. Cancer incidence and mortality in Ontario First Nations, 1968–1991 (Canada). Cancer Causes Control 2003;14:259–68
    1. Dignan M, Sharp P, Blinson K, et al. Development of a cervical cancer education program for native American women in North Carolina. J Cancer Educ 1995;9:235–42
    1. Reath J, Carey M. Breast and cervical cancer in indigenous women-overcoming barriers to early detection. Aust Fam Physician 2008;37:178–82
    1. Spence AR, Goggin P, Franco EL. Process of care failures in invasive cervical cancer: systematic review and meta-analysis. Prev Med 2007;45:93–106
    1. Moeller H. Tales about tuberculosis and colonization: the socio-cultural experience of tuberculosis in Nunavut. Alaska Med 2007;49:179–83
    1. Moeller H. Current tales about tuberculosis and colonialism in Nunavut. J Aboriginal Health 2010;5:1
    1. Healey SM, Aronson KJ, Mao Y, et al. Oncogenic human papillomavirus infection and cervical lesions in aboriginal women of Nunavut, Canada. Sex Transm Dis 2001;28:694–700
    1. Clarke HF, Joseph R, Deschamps M, et al. Reducing cervical cancer among First Nation women. Can Nurse 1998;94:36–41
    1. First Nations Centre Cancer of the Cervix in North American Indian Women. Ottawa: First Nations Centre at the National Aboriginal Health Organization; 2006
    1. International Agency for Research on Cancer (IARC); World Health Organization IARC Confirms Efficacy of Cervix Cancer Screening for Women 25–65 in Reducing Mortality. Press Release No.: 151. IARC Cervix Cancer Screening Meeting 2004. (accessed 12 May 2004).
    1. Stewart DE, Gagliardi A, Johnston M, et al. HPV Self-collection Guidelines Panel. Self-collected samples for testing of oncogenic human papillomavirus: a systematic review. J Obstet Gynaecol Can 2007;29:817–28
    1. Huynh J, Howard M, Lytwyn A. Self-collection for vaginal human papillomavirus testing: systematic review of studies asking women their perceptions. J Low Genit Tract Dis 2010;14:356–62
    1. Ogilvie G, Krajden M, Maginley J, et al. Feasibility of self-collection of specimens for human papillomavirus testing in hard-to-reach women. CMAJ 2007;177:480–3
    1. Stenvall H, Wikström I, Wilander E. High prevalence of oncogenic human papillomavirus in women not attending organized cytological screening. Acta Derm Venereol 2007;87:243–5
    1. Wikstrom I, Stenvall H, Wilander E. Attidudes to self-sampling of vaginal smear for human papillomavirus analysis among women not attending organized cytological screening. Acta Obstet Gynecol Scand 2007;86:720–5
    1. Sanner K, Wikström I, Strand A, et al. Self-sampling of the vaginal fluid at home combined with high-risk HPV testing. Br J Cancer 2009;101:871–4
    1. Moscicki AB, Widdice L, Ma Y, et al. Comparison of natural histories of human papillomavirus (HPV) detected by clinician- and self-sampling. Int J Cancer 2010;127:1882–92
    1. Bhatla N, Lalit D, Rajkumar AP, et al. Can human papillomavirus DNA testing of self-collected vaginal samples compare with physician-collected cervical samples and cytology for cervical cancer screening in developing countries? Cancer Epidemiol 2009;33:446–50
    1. Zehbe I, Wilander E. Nonisotopic ELISA-based detection of human papillomavirus-amplified DNA. Mod Pathol 1997;10:188–91
    1. Goleski V, Severini A, Dawood M, et al. Luminex based assay for multiplexed genotyping of 45 mucosal human papillomavirus types. Int J Antimicrob Agents 2009;34(Suppl 2):17–18
    1. Gravitt PE, Peyton CL, Alessi TQ, et al. Improved amplification of genital human papillomaviruses. J Clin Microbiol 2000;38:357–61
    1. Antonishyn NA, Horsman GB, Kelln RA, et al. Distribution of Human Papillomavirus Types Among Patients at a Colposcopy Referral Clinic in Saskatchewan, Canada. Arch Pathol Lab Med 2007;132:54–60
    1. Campbell I. Chi-squared and Fisher-Irwin tests of two-by-two tables with small sample recommendations. Stat Med 2007;26:3661–75
    1. de Villiers EM, Fauquet C, Broker TR, et al. Classification of papillomaviruses. Virology 2004;324:17–27
    1. Terai M, Burk RD. Identification and characterization of 3 novel genital human papillomaviruses by overlapping polymerase chain reaction: candHPV89, candHPV90, and candHPV91. J Infect Dis 2002;185:1794–7
    1. Statistics Canada (2006a) Aboriginal Identity (8), Age Groups (8), Area of Residence (6), Sex (3) and Selected Demographic, Cultural, Labour Force, Educational and Income Characteristics (233), for the Total Population of Canada, Provinces and Territories, 2006 Census - 20% Sample Data. (accessed 18 Oct 2010).
    1. Coutlée F, Hankins C, Lapointe N. Comparison between vaginal tampon and cervicovaginal lavage specimen collection for detection of human papillomavirus DNA by the polymerase chain reaction. The Canadian Women's HIV Study Group. J Med Virol 1997;51:42–7
    1. Leinonen M, Nieminen P, Kotaniemi-Talonen L, et al. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting. J Natl Cancer Inst 2009;101:1612–23
    1. Tota J, Mahmud SM, Ferenczy A, et al. Promising strategies for cervical cancer screening in the post-human papillomavirus vaccination era. Sex Health 2010;7:376–82
    1. Kitchener HC, Almonte M, Gilham C, et al. ARTISTIC Trial Study Group ARTISTIC: a randomised trial of human papillomavirus (HPV) testing in primary cervical screening. Health Technol Assess 2009;13:1–150iii–iv.
    1. Mayrand MH, Franco EL. Integrating novel primary- and secondary-prevention strategies: the next challenge for cervical cancer control. Future Oncol 2010;6:1725–33
    1. Ratnam S, Franco EL, Ferenczy A. Human papillomavirus testing for primary screening of cervical cancer precursors. Cancer Epidemiol Biomarkers Prev 2000;9:945–51
    1. Bell MC, Schmidt-Grimminger D, Patrick S, et al. There is a high prevalence of human papillomavirus infection in American Indian women of the Northern Plains. Gynecol Oncol 2007;107:236–41
    1. Howard M, Agarwal G, Lytwyn A. Accuracy of self-reports of Pap and mammography screening compared to medical record: a meta-analysis. Cancer Causes Control 2009;20:1–13

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren